Edgewise Therapeutics registers Phase 2 EQUINOX-HFpEF study of EDG-15400Aug 31Trial updateEDG-15400Edgewise Therapeutics, Inc.
Edgewise reports Q2 2026 results, positive Phase 2 HCM data and closed Servier saleAug 6Quarterly updateEDG-7500Edgewise Therapeutics, Inc.
Edgewise completes sevasemten sale to Servier, sharpens cardiovascular focusJul 13M&AEDG-7500Edgewise Therapeutics, Inc.
Sign inSign in